日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)

一项多中心随机 II 期试验,比较乐伐替尼联合依维莫司与卡博替尼治疗 PD-1 免疫检查点抑制剂治疗后进展的转移性透明细胞肾细胞癌患者的疗效(LenCabo)

Hahn, A W; Chahoud, J; Skelton, W P; Yuan, Y; Zurita-Saavedra, A J; Kovitz, C; Alhalabi, O; Campbell, M T; Jonasch, E; Lin, J K; Desai, M; Santos, M J M N; Hwang, H; Corn, P G; Msaouel, P; Tannir, N M

A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer

一项评估 telaglenastat (CB-839) 联合 nivolumab 治疗转移性黑色素瘤、肾细胞癌和非小细胞肺癌患者的安全性和有效性的 I/II 期研究

Gouda, M A; Voss, M H; Tawbi, H; Gordon, M; Tykodi, S S; Lam, E T; Vaishampayan, U; Tannir, N M; Chaves, J; Nikolinakos, P; Fan, A; Lee, R; McDermott, D; Shapiro, G I; Gandhi, L; Bhatia, S; Katragadda, V; Meric-Bernstam, F

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

纳武利尤单抗联合伊匹木单抗对比舒尼替尼一线治疗晚期肾细胞癌:来自 III 期 CheckMate 214 试验的 8 年延长随访疗效和安全性结果

Tannir, N M; Albigès, L; McDermott, D F; Burotto, M; Choueiri, T K; Hammers, H J; Barthélémy, P; Plimack, E R; Porta, C; George, S; Donskov, F; Atkins, M B; Gurney, H; Kollmannsberger, C K; Grimm, M-O; Barrios, C; Tomita, Y; Castellano, D; Grünwald, V; Rini, B I; Jiang, R; Desilva, H; Fedorov, V; Lee, C-W; Motzer, R J

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors

一线免疫检查点抑制剂治疗后接受二线VEGFR-TKI治疗的转移性透明细胞肾细胞癌患者的预后

Shah, A Y; Kotecha, R R; Lemke, E A; Chandramohan, A; Chaim, J L; Msaouel, P; Xiao, L; Gao, J; Campbell, M T; Zurita, A J; Wang, J; Corn, P G; Jonasch, E; Motzer, R J; Sharma, P; Voss, M H; Tannir, N M

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma

一项MK-2206与依维莫司治疗难治性肾细胞癌的随机II期研究

Jonasch, E; Hasanov, E; Corn, P G; Moss, T; Shaw, K R; Stovall, S; Marcott, V; Gan, B; Bird, S; Wang, X; Do, K A; Altamirano, P F; Zurita, A J; Doyle, L A; Lara, P N Jr; Tannir, N M

MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity

透明细胞肾细胞癌组织中的microRNA谱分析可能将肿瘤发生和复发与肥胖联系起来。

Shu, X; Hildebrandt, M A; Gu, J; Tannir, N M; Matin, S F; Karam, J A; Wood, C G; Wu, X

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies

接受其他靶向治疗后疾病进展的转移性透明细胞肾细胞癌患者,接受帕唑帕尼治疗后的预后

Matrana, M R; Duran, C; Shetty, A; Xiao, L; Atkinson, B J; Corn, P; Pagliaro, L C; Millikan, R E; Charnsangave, C; Jonasch, E; Tannir, N M

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.

对转移性肾细胞癌患者血浆中的细胞因子和血管生成因子 (CAF) 进行分析,以选择索拉非尼治疗

Zurita A J, Jonasch E, Wang X, Khajavi M, Yan S, Du D Z, Xu L, Herynk M H, McKee K S, Tran H T, Logothetis C J, Tannir N M, Heymach J V

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy

接受靶向治疗而不行细胞减灭性肾切除术的转移性肾细胞癌患者的预后

Richey, S L; Culp, S H; Jonasch, E; Corn, P G; Pagliaro, L C; Tamboli, P; Patel, K K; Matin, S F; Wood, C G; Tannir, N M